Polymyositis News

Patients with antisynthetase syndrome who test positive for anti-citrullinated peptide / protein antibodies may also have rheumatoid arthritis and may not respond well to conventional treatments, according to research published in Medicine.

Much of the news offered by Healio.com/Rheumatology in June was related to sessions presented at the European League Against Rheumatism Annual European Congress of Rheumatology, which took place from June 10-13 in Rome.

Patients with polymyositis and dermatomyositis had an altered serum fatty acid profile compared with healthy control participants, and immunosuppression further altered the fatty acid profile, according to data presented at the European League Against Rheumatism Annual European Congress of Rheumatology.

Only a small number of patients with rheumatic diseases said fatigue-related communication with a rheumatologist was not important; however, less than half of patients studied were satisfied with actual communication, and more than three-quarters of patients reported that the fatigue-related communication was initiated by the patient, according to survey results presented at the European League Against Rheumatism Annual European Congress of Rheumatology.

Patients with antisynthetase syndrome who test positively for anti-citrullinated peptide antibodies may have overlapping rheumatoid arthritis or another rheumatic disease, according to recently published study data.

Neither methotrexate nor cyclosporine improved symptoms in patients with dermatomyositis or polymyositis who did not respond fully to treatment with glucocorticoids, according to recently published research.

Padlock Therapeutics announced it has entered into an agreement with GSK to license a collection of assets and intellectual property from GSK intended to develop treatments for autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis.

Patients with dermatomyositis and polymyositis had higher levels of osteopontin in skeletal muscles and serum than control participants, according to researchers’ findings.

Serum levels of soluble CD163 were significantly elevated in patients with polymyositis and dermatomyositis, and levels correlated with disease activity and CD163+ macrophage infiltration, suggesting soluble CD163 may hold potential as a biomarker, according to recently published research.

The inappropriate use of NSAIDs, defined by the Italian Agency of Medicines as use for 21 days or more, for chronic pain associated with osteoarthritis, rheumatoid arthritis and other conditions may be prevalent in European patients, according to recently published research.